高度血清性卵巢癌患者治疗反应的新免疫表型
Cecilie Fredvik Torkildsen1,2, Marie Austdal3, Anders Hagen Jarmund4
1Department of Obstetrics and Gynecology, Stavanger University Hospital, Stavanger, Norway.
Frontiers in immunology
|July 1, 2024
概括
高度血清性卵巢癌患者在诊断时表现出不同的免疫表型. 这些免疫特征可以指导治疗选择,并改善卵巢癌的预后.
科学领域:
- 妇科瘤学 妇科瘤学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 高度血清性卵巢癌 (HGSOC) 尽管治疗进展,预后不佳.
- 细胞还原性手术对生存至关重要,需要工具来预测治疗反应.
- 血清细胞因子分析提供了对免疫状态的洞察力,但在HGSOC治疗中未得到充分利用.
研究的目的:
- 鉴定HGSOC患者治疗前和治疗期间免疫反应的特征.
- 为了确定血清细胞因子生物标志物用于治疗分层和预后.
- 探索免疫表型,手术评分和治疗结果之间的关系.
主要方法:
- 从诊断到响应评估时,从22名HGSOC患者收集了长度血清样本.
- 患者被分配到初级细胞削减手术或新辅助化疗 (NACT).
- 使用Bio-Plex 200分析血清细胞因子,以确定免疫表型 (免疫高与免疫高). 免疫能力较低).
主要成果:
- 在诊断时确定了两个不同的免疫表型 (免疫高和免疫低),与腹腔镜得分和治疗分配相关.
- 接受细胞削减手术的免疫高患者表现出比免疫低患者更好的无进展生存率.
- 手术诱导的过渡性细胞因子变化 (例如,IL-6上调,IP-10,Eotaxin,IL-4,IL-7下调),随着时间的推移水平下降.
结论:
- 在HGSOC患者中,明显的治疗前免疫表型可以告知治疗分层和预后.
- 血清细胞因子分析显示,它有可能成为评估卵巢癌治疗反应的新生物标志物.
- 对这些免疫表型的进一步验证可能会加强对HGSOC的个性化治疗策略.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


